Európska únia - angličtina - EMA (European Medicines Agency)

gilead sciences ireland uc - elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide - hiv infections - antivirals for systemic use, - genvoya is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (hiv 1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.,

Kanada - angličtina - Health Canada

janssen inc - darunavir (darunavir ethanolate); cobicistat - tablet - 800mg; 150mg - darunavir (darunavir ethanolate) 800mg; cobicistat 150mg - hiv protease inhibitors

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - cobicistat; tenofovir disoproxil fumarate; emtricitabine; elvitegravir -

Kanada - angličtina - Health Canada

bristol-myers squibb canada - atazanavir (atazanavir sulfate); cobicistat - tablet - 300mg; 150mg - atazanavir (atazanavir sulfate) 300mg; cobicistat 150mg - hiv protease inhibitors

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - tenofovir alafenamide; emtricitabine; cobicistat; elvitegravir - tablet - 10mg ; 200mg ; 150mg ; 150mg

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - darunavir ethanolate; cobicistat - tablet - 800mg ; 150mg

Kanada - angličtina - Health Canada

gilead sciences canada inc - emtricitabine; elvitegravir; tenofovir disoproxil fumarate; cobicistat - tablet - 200mg; 150mg; 300mg; 150mg - emtricitabine 200mg; elvitegravir 150mg; tenofovir disoproxil fumarate 300mg; cobicistat 150mg - hiv integrase inhibitors

Kanada - angličtina - Health Canada

gilead sciences canada inc - emtricitabine; elvitegravir; tenofovir alafenamide (tenofovir alafenamide hemifumarate); cobicistat - tablet - 200mg; 150mg; 10mg; 150mg - emtricitabine 200mg; elvitegravir 150mg; tenofovir alafenamide (tenofovir alafenamide hemifumarate) 10mg; cobicistat 150mg - hiv integrase inhibitors

Spojené štáty - angličtina - NLM (National Library of Medicine)

a-s medication solutions - elvitegravir (unii: 4gdq854u53) (elvitegravir - unii:4gdq854u53), cobicistat (unii: lw2e03m5pg) (cobicistat - unii:lw2e03m5pg), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir alafenamide fumarate (unii: fwf6q91tzo) (tenofovir anhydrous - unii:w4hfe001u5) - elvitegravir 150 mg - genvoya is indicated as a complete regimen for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (hiv-1 rna less than 50 copies per ml) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of genvoya [see clinical studies (14)]. coadministration of genvoya is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. these drugs and other contraindicated drugs (which may lead to reduced efficacy of genvoya and possible resistance) are listed in table 1 [see drug interactions (7.5) and clinical pharmacology (12.3)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors

Malajzia - angličtina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

gilead sciences malaysia sdn. bhd. - emtricitabine; tenofovir alafenamide fumarate; elvitegravir; cobicistat on silicon dioxide -